Multiplex immunofluorescence (mIF) combines the spatial information from immunohistochemistry (IHC) with multimarker phenotypes. Recent advances in mIF technology have made it possible for researchers to develop novel custom panels, but additional considerations must be taken into account in order to produce a panel which performs at least as well as IHC on a marker-by-marker basis and avoids any undesirable interactions between detection of the targets and neighboring visible light spectra.
In this webinar, Michael J. Surace, Scientist II at AstraZeneca, will explore the biological and technical considerations when designing a panel, describe a linear process for developing, testing, and optimizing a panel, and provide an approach for technical validation of multiplex panels that detects and addresses known risks.
Key learning objectives:
The live webinar and Q&A session will take place on Thursday, March 26, at:
SelectScience runs 3-4 webinars a month across various scientific topics, discover more of our upcoming webinars>>